0.5551

0.02% 0.000100

Century Therapeutics Inc (IPSC)

Overview News Price History Option Chain Financials Discussions Forecast

Century Therapeutics Inc stock is traded at $0.5551, with a volume of 214.23K. It is up +0.02% in the last 24 hours and down -2.63% over the past month. Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Previous Close:

$0.555

Open:

$0.5605

24h Volume:

214.23K

Relative Volume:

0.30

Market Cap:

$54.69M

Revenue:

$2.24M

Net Income/Loss:

$-136.67M

P/E Ratio:

-0.2424

EPS:

-2.29

Net Cash Flow:

$-102.08M

1W Performance:

-2.20%

1M Performance:

-2.63%

6M Performance:

-49.99%

1Y Performance:

-75.55%

1-Day Range:

$0.5501

$0.5643

1-Week Range:

$0.5187

$0.5671

52-Week Range:

$0.3418

$3.29

Century Therapeutics Inc Stock (IPSC) Company Profile

Name

Century Therapeutics Inc

Sector

Healthcare (1160)

Industry

Biotechnology (651)

Phone

215-981-4000

Address

25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA

Employee

165

Twitter

Next Earnings Date

2025-03-19

Latest SEC Filings

IPSC's Discussions on Twitter

Compare IPSC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IPSC Century Therapeutics Inc	0.5551	54.69M	2.24M	-136.67M	-102.08M	-2.29
VRTX Vertex Pharmaceuticals Inc	459.62	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.36	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	331.91	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	543.48	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-08-24	Initiated	Rodman & Renshaw	Buy
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Dec-27-22	Initiated	Chardan Capital Markets	Buy
Oct-31-22	Initiated	Guggenheim	Buy
Oct-10-22	Initiated	Canaccord Genuity	Buy
May-23-22	Initiated	H.C. Wainwright	Buy
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	BofA Securities	Buy
Jul-13-21	Initiated	JP Morgan	Overweight
Jul-13-21	Initiated	Piper Sandler	Overweight

View All

Century Therapeutics Inc Stock (IPSC) Latest News

Jun 16, 2025

Century Therapeutics Holds Annual Stockholder Meeting By Investing.com - Investing.com South Africa

Jun 16, 2025

Century Therapeutics Holds Annual Stockholder Meeting - Investing.com Australia

Jun 16, 2025

Century Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 16, 2025

Jun 14, 2025

66,797 Shares in Century Therapeutics, Inc. (NASDAQ:IPSC) Acquired by Two Sigma Investments LP - Defense World

Jun 14, 2025

Jun 10, 2025

Jane Street Group LLC Increases Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World

Jun 10, 2025

Jun 09, 2025

Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Acquired by Squarepoint Ops LLC - Defense World

Jun 09, 2025

Two Sigma Advisers LP Takes $52,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World

Jun 09, 2025

Jun 07, 2025

Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World

Jun 07, 2025

Jun 06, 2025

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - sharewise

Jun 06, 2025

Jun 04, 2025

Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress - MSN

Jun 04, 2025

Jun 03, 2025

Deutsche Bank AG Purchases 173,849 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World

Jun 03, 2025

Millennium Management LLC Grows Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World

Jun 03, 2025

May 30, 2025

Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World

May 30, 2025

May 29, 2025

Brokers Issue Forecasts for IPSC Q1 Earnings - Defense World

May 29, 2025

May 28, 2025

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress - GlobeNewswire

May 28, 2025

May 23, 2025

Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline - MSN

May 19, 2025

Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating - marketscreener.com

May 19, 2025

May 18, 2025

Chardan Capital Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $6.00 - Defense World

May 18, 2025

May 16, 2025

Chardan Capital Lowers Price Target for Century Therapeutics (IP - GuruFocus

May 16, 2025

Chardan Capital Lowers Price Target for Century Therapeutics (IPSC) | IPSC Stock News - GuruFocus

May 16, 2025

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 16, 2025

May 15, 2025